Allogene Therapeutics (ALLO) 8-KOther Events

Due to the exceptional circumstances related to the COVID-19 global pandemic, Les Laboratoires Servier SAS and Institut de Recherches Internationales Servier SAS (collectively, “Servier”) has informed Allogene Therapeutics, Inc. (“Allogene”) of its decision to halt recruitment in the PALL and CALM clinical trials evaluating UCART19 in patients with relapsed or refractory acute lymphoblastic leukemia (“R/R ALL”).

Under the Allogene and Servier collaboration aiming to develop allogeneic chimeric antigen receptor (“CAR”) T cell therapies directed at CD19 using Cellectis TALEN technology, licensed to Servier, Servier is the sponsor of the Phase 1 clinical trials of UCART19 for patients with R/R ALL while Allogene is the sponsor of the Phase 1 clinical trial of ALLO-501 (the “ALPHA trial”) for patients with relapsed or refractory non-Hodgkin lymphoma (“R/R NHL”).

At this time, Allogene is continuing to enroll R/R NHL patients in the ALPHA trial and expects to report initial data from the trial in the second quarter of 2020. Allogene is also continuing to enroll patients with relapsed or refractory multiple myeloma in the Phase 1 clinical trial of ALLO-715 (the “UNIVERISAL trial”). However, enrollment of new patients in both the ALPHA trial and UNIVERSAL trial and the ability to conduct patient follow-up will likely be impacted by the COVID-19 pandemic.

In addition, in response to the spread of COVID-19 and state and local orders, we have closed our headquarters with our administrative employees continuing their work outside of our offices and limited the number of staff in any given research and development laboratory. Construction of our manufacturing facility in Newark, California, has also been interrupted and may in the future be interrupted due to the COVID-19 pandemic.

The exact timing of delays and overall impact to our business, preclinical studies and clinical trials is currently unknown, and we are monitoring the COVID-19 outbreak as it continues to rapidly evolve.

In light of recent developments relating to the COVID-19 global pandemic, Allogene is supplementing the risk factors previously disclosed in Item 1A. of its Annual Report on Form 10-K for the year ended December 31, 2019, as filed with the Securities and Exchange Commission on February 27, 2020, to include the following risk factor under the heading “Risks Related to our Business and Industry”:

Public health crises such as pandemics or similar outbreaks could adversely impact our business. In December 2019, a novel strain of coronavirus, SARS-CoV-2, which causes coronavirus disease 2019 (COVID-19), surfaced in Wuhan, China. Since then, COVID-19 has spread to multiple countries, including the United States and Europe. As a result of the COVID-19 outbreak, or similar pandemics, and government response to pandemics, we have and may in the future experience disruptions that could severely impact our business, preclinical studies and clinical trials, including:

These and other factors arising from the COVID-19 pandemic could worsen in countries that are already afflicted with COVID-19, could continue to spread to additional countries, or could return to countries where the pandemic has been partially contained, each of which could further adversely impact our ability to conduct clinical trials and our business generally, and could have a material adverse impact on our operations and financial condition and results. State and local government response to the pandemic has included "shelter in place", "stay at home" and similar types of orders, which have limited travel and business operations in our location, the location of our clinical trial sites, and the location of key vendors, including our contract manufacturing organization. While we, our clinical trials sites and certain of our vendors, including our contract manufacturing organization, are currently exempt from the orders for certain operations, any of the applicable exemptions may be curtailed or revoked, which would further adversely impact our business.

In addition, the trading prices for our common stock and other biopharmaceutical companies have been highly volatile as a result of the COVID-19 pandemic. As a result, we may face difficulties raising capital through sales of our common stock or such sales may be on unfavorable terms.

The COVID-19 outbreak continues to rapidly evolve. The extent to which the outbreak may impact our business, preclinical studies and clinical trials will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread of the disease, the duration of the outbreak, travel restrictions and actions to contain the outbreak or treat its impact, such as social distancing and quarantines or lock-downs in the United States and other countries, business closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain and treat the disease.

This Current Report on Form 8-K contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Forward-looking statements are usually identified by the use of words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “seeks,” “should,” “will,” and variations of such words or similar expressions. Allogene intends these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements, including statements regarding the timing of enrollment in its clinical trials, delays in the commencement of its planned clinical trials, non-clinical experiments and investigational new drug application-enabling studies, its development strategy for its product candidates, the timing, progress and results of clinical trials, preclinical studies and other research and development activities and the potential utility of its product candidates, and the impact of COVID-19 on its preclinical studies, clinical trials, business, financial condition and results of operations, reflect Allogene’s current views about its plans, intentions, expectations, strategies and prospects, which are based on the information currently available to Allogene and on assumptions it has made. Although Allogene believes that its plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, Allogene can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a number of risks, uncertainties and assumptions, including, but not limited to, those risks set forth in the Risk Factors section of Allogene’s most recent Annual Report on Form 10-K and its other Securities and Exchange Commission filings. Moreover, Allogene operates in a very competitive and rapidly changing environment in which new risks emerge from time to time. These forward-looking statements are based upon the current expectations and beliefs of Allogene’s management as of the date of this Current Report on Form 8-K, and are subject to certain risks and uncertainties that could cause actual results to differ materially from those

described in the forward-looking statements. Except as required by applicable law, Allogene assumes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.